靶向PD-1/PD-L1的新策略:降解剂、双功能分子及共价抑制剂
New strategies for targeting PD-1/PD-L1:degraders,bifunctional molecules and covalent inhibitors
王志杰 1廖晓彤 2郭霞 3陈建军2
作者信息
- 1. 南方医科大学深圳医院, 深圳 518100;南方医科大学药学院, 广州 510515
- 2. 南方医科大学药学院, 广州 510515
- 3. 南方医科大学深圳医院, 深圳 518100
- 折叠
摘要
靶向细胞程序性死亡受体-1(programmed cell death protein-1,PD-1)/细胞程序性死亡配体-1(programmed cell death ligand-1,PD-L1)已成为最具前景的肿瘤免疫治疗靶点之一.目前,PD-1/PD-L1单克隆抗体药物及小分子抑制剂都面临着相应的发展瓶颈,许多研究者尝试探索不同的策略以阻断PD-L1/PD-L1通路,期望改善肿瘤治疗的效果.本文总结了靶向PD-L1的降解剂、双功能分子及共价抑制剂,旨在为PD-1/PD-L1药物的开发提供有益的思路.
Abstract
Programmed cell death protein-1(PD-1)/programmed cell death ligand-1(PD-L1)has been considered to be one of the most promising targets for tumor immunotherapy.At present,both monoclonal antibody drugs and small molecule inhibitors targeting PD-1/PD-L1 are facing bottlenecks.Numerous researchers have tried to explore different strategies to block the PD-L1/PD-L1 pathway,hoping to improve the effects of tumor immunotherapy.This review focuses on the degraders,bifunctional molecules and covalent inhibitors that target PD-L1,aiming to provide inspiring insights for the development of anti-PD-1/PD-L1 drugs.
关键词
PD-1/PD-L1/肿瘤免疫/降解剂/双功能分子/共价抑制剂Key words
PD-1/PD-L1/tumor immunotherapy/degraders/bifunctional molecules/covalent inhibitors引用本文复制引用
基金项目
国家自然科学基金(82173668)
国家自然科学基金(82373706)
出版年
2024
国家科技期刊平台
NSTL
万方数据